Another Possible Treatment Option for Intermediate-Stage Liver Cancer
Progression-free survival (PFS) in intermediate-stage hepatocellular carcinoma (HCC) improved by almost 5 months when a targeted agent and immunotherapy were...
option
Imfinzi-Imjudo dual immunotherapy offers new option for 1st-line treatment of liver cancer < Pharma < Article
As AstraZeneca launches Imjudo (tremelimumab) without health insurance coverage in May, Korean liver cancer patients will likely have...
JHCC adds innovative treatment option for liver cancer patients
Liver cancer patient Ron Clement was able to quickly get back to favorite hobbies, including birdwatching, after undergoing a type...
